Evidence map›Paper›PMID 34041413›Full record

ArticleContemporary clinical trials communications2021

Prediction of response to Certolizumab-Pegol in rheumatoid arthritis (PreCePRA) by functional MRI of the brain - Study protocol for a randomized double-blind controlled study.

H M Schenker, K Tascilar, L Konerth, M Sergeeva, J Prade, S Strobelt, A Kleyer, D Simon, L Mendez, M Hagen and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Contemporary clinical trials communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 1 country.

H M SchenkerDepartment of Internal Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Germany.
K TascilarDepartment of Internal Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Germany.
L KonerthInstitute of Pharmacology and Toxicology, University of Erlangen-Nuremberg, Germany.
M SergeevaInstitute of Pharmacology and Toxicology, University of Erlangen-Nuremberg, Germany.
J PradeInstitute of Pharmacology and Toxicology, University of Erlangen-Nuremberg, Germany.
S StrobeltInstitute of Pharmacology and Toxicology, University of Erlangen-Nuremberg, Germany.
A KleyerDepartment of Internal Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Germany.
D SimonDepartment of Internal Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Germany.
L MendezDepartment of Internal Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Germany.
M HagenDepartment of Internal Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Germany.
V SchönauDepartment of Internal Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Germany.
A HueberClinic Bamberg, Section Rheumatology, Bamberg, Germany.
J RoeschDepartment of Neuroradiology, University of Erlangen-Nuremberg, Germany.
A DörflerDepartment of Neuroradiology, University of Erlangen-Nuremberg, Germany.
A HessInstitute of Pharmacology and Toxicology, University of Erlangen-Nuremberg, Germany.
G SchettDepartment of Internal Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Germany.
J RechDepartment of Internal Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Germany.
Friedrich-Alexander-Universität Erlangen-Nürnberg · DEUniversity of Bamberg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTumor necrosis factor inhibitors (TNFi) signify a major advance in the treatment of rheumatoid arthritis (RA). However, treatment success initially remains uncertain as approximately half of the patients do not respond adequately to TNFi. Thus, an unmet need exists to better predict therapeutic outcome of biologicals.

objectivesWe investigated whether brain activity associated with arthritis measured by functional magnetic resonance imaging (fMRI) of the brain can serve as a predictor of response to TNFi in RA patients.

methodsPreCePRA is a multi-center, randomized, double-blind, placebo-controlled fMRI trial on patients with RA [1] [2]. Active RA patients failing csDMARDs therapy with a DAS28 > 3.2 and at least three tender and/or swollen joints underwent a brain BOLD (blood-oxygen-level dependent) fMRI scan upon joint compression at screening. Patients were then randomized into a 12-week double-blinded treatment phase with 200 mg Certolizumab Pegol (CZP) every two weeks (arm 1: fMRI BOLD signal activated volume > 2000 voxel, i.e. 2 cm

conclusionWe hypothesize that high-level central nervous representation of pain in patients with rheumatoid arthritis predicts response to the TNFi CZP which we further investigate in the PreCePRA trial.

Indexed as

functional MRINeuroimagingRheumatoid arthritisTNF inhibition

Identifiers

PMID34041413
PMCPMC8144682
OpenAlexW3158361512

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.